Jefferies Maintains Buy on Allogene Therapeutics, Raises Price Target to $10

Benzinga Newsdesk www.benzinga.com Positive 75.5%

Neg 0% Neu 0% Pos 75.5%

Jefferies analyst Roger Song maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and raises the price target from $6 to $10.